{"entity":{"id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","aka":["SOUND-MCL"],"tldr":"A phase 2 trial of Acalabrutinib, Rituximab in mantle cell lymphoma, run by AstraZeneca, now recruiting.","summary":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain is a phase 2 interventional study registered as NCT07029737 by AstraZeneca, with 55 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-12-31. Interventions recorded: Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy. Conditions listed: Mantle-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07029737","url":"https://clinicaltrials.gov/study/NCT07029737"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib","rituximab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07029737","phase":"2","setting":"The SOUND-MCL Study: A Single-arm, Open-label, Multicenter, Phase II Study of Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","sponsor":"AstraZeneca","participation":[{"nct":"NCT07029737","source":"https://clinicaltrials.gov/study/NCT07029737","fetchedAt":"2026-10-07T16:55:22.250Z","studySha256":"9a430c5b1c0b6bbc9d9b8e0e08997bca2bb603c1daa77918eb05ae7c3c4b9b53","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-02","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":55,"enrolmentType":"ESTIMATED","siteCount":22,"recruitingSiteCount":21,"countries":["Spain"]}],"started":"2025-09-05","startedType":"actual","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07029737/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}